vertically from too great a distance (Fig. 2, iii) penetration of the skin was inadequate. The correct depth of injection was achieved (Fig. 2, iv) by pushing up a small " hump " of skin in front of the nozzle when the gun was fired at an angle of 30 to 45 degrees to the skin. A weal approximately 5-8 mm. in diameter could always be seen when the vaccine had been correctly given. A smaller or an absent weal was not taken as an indication for a second " shot."
Every year approximately 150 alcoholic patients are admitted to the alcoholic unit of St. Bernard's Hospital. A very large percentage of the patients are still intoxicated on arrival after a drinking bout, and their treatment therefore presents three different needs: to dry out the patients with as little inconvenience as possible; to discover and treat any complicating physical or psychiatric conditions ; and to make the patient accept alcoholism as one of his basic problems and to help him overcome it by a long-term treatment and rehabilitation programme (Glatt, 1955) .
The present report is concerned with the first type of therapy -that is, treatment of acute alcoholic intoxication and of withdrawal symptoms directly after the patient's admission. This treatment is most urgently needed during the first days of admission, when immediate withdrawal of alcohol may lead to pronounced symptoms. For the purpose of relieving the patient's psychomotor agitation, a number of drugs with sedative and tranquillizing properties have been used over the years at our alcoholic units. Most of these substances were thought to be of value when assessed clinically. However, when controlled trials were carried out with some of them-chlorpromazine, promazine, reserpine-their effect was not significantly better statistically than that of the placebo (Glatt, 1959) .
Some time ago a new sedative, chlormethiazole (Heminevrin), was brought to our attention, and we used it for about one year as a routine treatment during the acute stage of alcoholic intoxication. The results of this pilot study were promising, and it was thought worth while to attempt to find out Charonnat et al. (1953) found that the shock-producing effect of intravenously injected vitamin B1 was related to the pyrimidine part of this molecule (Fig. 1) . The thiazole part of the molecule, on the other hand, had a protective effect against convulsions induced by the pyrimidine fraction. The pharmacological properties of a number of derivatives of the thiazole fraction were investigated, and chlormethiazole, which is the ethandisulphonate of 4-methyl-5-,/-chlorethyl-thiazole ( Fig. 1 ) was found to possess the most pronounced sedative and anticonvulsive effect (Charonnat et al., 1956 (Charonnat et al., , 1957a (Charonnat et al., , 1957b (Charonnat et al., , 1958 .
In rabbits and mice the substance showed anticonvulsive, sedative, and, in higher dosage, hypnotic effects (Charonnat et al., 1957a (Charonnat et al., , 1958 . In mice the LD50 was found to be about 20 times lower than that of pentobarbitone (Charronat et al., 1957b) , and no teratogenic effect was observed in rats (Z. Hadidian and E. R. Smith, personal communication, 1963) . Oral absorption of chlormethiazole is rapid and most of it is excreted in the urine within three hours (Allgen et al., 1963) .
A comprehensive review of the pharmacology of chlormethiazole has been published by Svedin (1963 Reports on the clinical application of chlormethiazole in psychiatry mainly describe its use in the treatment of delirium tremens and withdrawal symptoms in long-standing alcoholism (Laborit et al., 1957 (Laborit et al., , 1958 Royer et al., 1958a; Osterman et al., 1959; Giacobini and Salum. 1961 ; Asander, 1962; Salum 1963; Sattes, 1964a) as well as in the treatment of psychomotoric agitation and anxiety states (Laborit et al., 1957; Follin et al., 1958 ; Osterman et al., 1959 ; Sattes, 1964a) .
The anticonvulsive action of chlormethiazole has been employed in treatment of status epilepticus (Royer et al., 1958b; Poire et al., 1963 ; Krause, 1964' and in the fits of measles (Skoldenberg, 1961) . In anaesthesia a good effect was obtained in geriatric patients by Gabrielsson et al. (1961) and Jorkensen (1963) , but Dundee (1958) did not find it to be a satisfactory intravenous agent.
Material and Methods
The patients consisted of male and female alcoholics admitted to St. Bernard's Hospital in 1963-4 in varying stages of alcoholic intoxication. On admission, personal data, social characteristics, and the alcohol history of the patients, as well as symptoms and data regarding their clinical condition, were registered in a form including 82 headings. During the trial period the symptoms and the clinical condition were assessed each day, changes being included in evaluating the results.
An overall assessment of treatment was attempted by three different means. (1) On the first, second, and third days of the trial the condition of the patient was assessed by a doctor. Clinically, the course of disease was classified as being greatly improved, improved, unchanged, worse, or much worse. (2) At the end of the trial period the patient was asked to give his BRITIsH MEDICAL JOURNAL opinion regarding the effect of the medication. The results of therapy thus were graded as good, satisfactory, or nil. (3) At the end of the trial period the doctor made a clinical assessment of whether the patient had been receiving the active tablet or the placebo, giving his reasons.
Routine laboratory tests were done on admission of the patient and repeated after four to six weeks if there was any abnormality.
The investigation was carried out as a double-blind trial. Tablets containing 500 mg. of chlormethiazole were compared with placebo tablets. In order to make the placebo tablets indistinguishable from the active tablet, 10 mg. of chlormethiazole was added to the coating of each placebo tablet, an amount which would be too small to have any clinical effect.
The following dosage scheme was applied: The test tablets for each patient were provided with a serial number and distributed within the series by help of a table of random numbers. Details concerning dosage were registered in the form.
As half of the patients received placebo, an anticonvulsive, phenytoin, was given to all patients.
Results
A total of 102 patients were included in the trial. In two of the forms the code-number of the test tablet was missing, and three patients did not complete the course of treatment (two chlormethiazole, one placebo), so they had to be excluded. The final number of cases in the trial were thus 97.
The sex distribution is evident from Table I . About 70% of the patients belonged to the age group 30-S50 years and roughly one-half were living with their family. Fifty-six patients belonged to social class III, 19 to class I and II, and the remainder to IV and V. Data concerning the alcoholic history of the patients as well as a rough classification of their condition are given in Table I . All but one patient included in the trial had been drinking up to admission; one had stopped drinking two days previously but was showing withdrawal symptoms. Whenever information regarding the alcoholic history of the patient was regarded as being unreliable, these data were not introduced in the forms (see footnotes to Table I ).
There were no gross differences between the two treatment groups with regard to alcoholic history. Possibly more advanced cases happen to be somewhat over-represented in the chlormethiazole group.
Most of the patients were in a good or satisfactory general and nutritional condition. Liver complications were found in It is evident from the columns showing the distribution of the different symptoms in the two treatment groups that there was a general trend towards a lower frequency of initial symptoms in the placebo group.
In addition to the symptoms described in Table II , eight patients had paranoid ideas, three reported nightmares, and two experienced hallucinations.
During the trial period almost all of the individual symptoms improved more rapidly in the group treated with the active tablets, especially in respect of the psychiatric symptoms. Moreover, a larger number of patients in the placebo group developed symptoms after the starting of treatment which they had not had on admission. This was most clearly shown in regard to depression. On admission 57% of the patients in the chlormethiazole group and 50% of those in the placebo group showed depression (Table II) . Of 21 patients in the chlormethiazole group who were not depressed at the time of admission, two developed depression during the trial period, while the corresponding figures for the placebo group were 10 out of 24. This difference is probably statistically significant (0.05>P>0.01). Thus a total of 30 patients in the chlormethiazole group and 33 in the placebo group showed depression at some time during the trial period. By the end of the trial, or the sixth day, 29 out of 30 depressed patients in the chlormethiazole group had improved or were free from the symptom, while in 10 out of 33 patients in the placebo group depression was still unchanged. This difference is statistically significant (0.01>P>0.001).
The incidence of sedation during the trial period amounted to 53% in the chlormethiazole group and 25% in the placebo group. This difference is statistically significant (X2 = 8.01 0.01>P>0.001).
The overall assessment of the effect of treatment by the doctor on the first, second, and third days of the trial is shown in Fig. 2 patients were "improved " on the first, second, and third days of the trial respectively. In the placebo group the respective percentages were 22, 27, and 41. These differences between the trial groups were statistically significant on the first and third days of treatment and highly significant on the second day of the trial period. When at the end of the trial period the patients were asked to give their opinion on the value of the medication, only three had not noticed any effect of treatment with chlormethiazole. In the placebo group 22 patients answered in the negative. This difference is statistically highly significant (x2 = 18.69; P<0.001).
The doctor's answer at the end of the trial period when asked to decide which one of the tablets had been used during the trial was correct in more than 70 % of the cases for both preparations, which is statistically highly significant (P<0.001). In almost 60% of the material the decision for the clinical assessment was determined on the course of the symptoms. The presence (chlormethiazole group) or lack (placebo group) of sedation was given as a reason for the assessment in about 20% of cases. In about 10 cases the presence of side-effects determined the decision in favour of the active tablet and in 13 cases no explanation has been given.
Serious side-effects which made it necessary to change treatment were not observed in this trial. In one patient (Case 41) receiving placebo an episode of pronounced confusion with nightmares, excitation, dizziness, and nausea was observed.
Drowsiness was seen in four patients (two chlormethiazole, two placebo). In 14 patients sneezing reflex was observed (11 chlormethiazole, 3 placebo) and four had cough attacks (two chlormethiazole, two placebo).
The laboratory investigations carried out during the trial did not reveal any adverse effect of the drug. Discussion The admission of ,n alcoholic patient to hospital, resulting in a more regular life, improved nutritional condition, incorporation in the " Group," etc., certainly has a bearing upon the consequences of a drinking episode. Admission to the alcoholic unit can therefore by itself be expected to produce some amelioration of symptoms. In the present investigations 20-40% of the placebo group improved during the first three days of their hospital stay without the administration of a sedative drug. However, the present investigation also shows that administration of chlormethiazole brought relief from withdrawal symptoms in twice as many patients as in the placebo group.
That this effect is at least partly correlated to the sedative action of the drug may be seen from the fact that of 33 patients who had improved in the chlormethiazole group (Fig. 2) 23 also showed some degree of sedation, while of 16 patients receiving chlormethiazole, and whose general condition was unchanged, only three were also sedated. This difference in frequency of sedation was statistically highly significant (P<0.001).
When a fixed dosage scheme was used in this trial-which has been based on experience from the Beckomberga Hospital, Stockholm (I. Salum, personal communication, 1962) Gastager et al. (1964), and Sattes (1964b) reported satisfactory results in treatment of acute intoxication and when using similar doses.
From the above evidence, and the experience gained from our own trial, it might be assumed that at least some of our patients received the active drug in quite low dosage. Nevertheless, only three patients receiving chlormethiazole thought that treatment had no effect, while more than half of those receiving placebo tablets thought so. A further trial with an individual dosage scheme is now under way. Salum (1963) stated that in her opinion the development of delirium tremens from milder stages of alcoholic disease in the course of treatment with chlormethiazole probably indicates inadequate dosage.
In our material more patients in the placebo group developed new symptoms-in particular depression-after admission than was the case in the group receiving the active tablet (Glatt and George, 1964) .1 It has been advocated that the drug should not be given in depression (Brit. med. f., 1964). In this series over 50% of the alcoholic patients were in a state of reactive depression when admitted for treatment, and an untoward effect of the drug on depression would undoubtedly have become evident. No such evidence could be found in our trial, and it seems important to stress that in our experience depression is no contraindication for use of the drug.
Comparison of a placebo with an active drug that has an effect which can be easily recognized, such as sedation, may carry a risk that a discrimination between the tablets is possible. The same is true when characteristic side-effects of a drug are known-for example, sneeze reflex.
It seemed to be of interest to find out if the presence of a characteristic side-effect-that is, sneezing during the first three days of the trial period-had any bearing upon the investigator's assessment of the drug-effect. Of 33 patients who were classified as improved on the second day of the trial seven complained of sneeze reflex. Of 16 patients whose condition was unchanged four complained of the said side-effect. If the assessment of drug-effect had been biased by the presence of sneezing at that stage of the trial a higher proportion of sneezereflex cases would have been expected in the improved group. This was not the case.
In the present investigation all patients were receiving an anticonvulsive in addition to the trial tablets. This medication was given in order to protect the placebo patients from convulsions: chlormethiazole has an anticonvulsive action in itself and the administration of phenytoin also in this group was necessary to meet the demands of the double-blind technique.
With the dosage of chlormethiazole employed in this trial the only side-effect observed was the presence of sneeze reflex. A heavy degree of sedation occurred in a number of those receiving the active drug, and difficulties in predicting the degree of hypnotic effect in the individual case might occasionally present problems. In this respect our experience corresponds to the views expressed by Salum (1963) , who points out that sleep may sometimes be deeper than intended (with marked miosis). Sattes (1964b) , who used chlormethiazole in very high doses, describes no serious side-effect, though his patients complained of the taste and smell of the tablets. Such complaints were very rare with us. ' In the Table published 
Summary
A controlled trial has been carried out in which chlormethiazole (Heminevrin) and a placebo are compared in the treatment of withdrawal symptoms in alcoholic patients. A statistically significant difference was found between the active and placebo groups. No serious side-effects were observed.
No evidence could be adduced indicating that chlormethiazole was contraindicated in depression. This finding is not in line with views previously expressed. The results of this trial show chlormethiazole to be a valuable drug in the treatment of withdrawal symptoms in alcoholics, although in view of the possible risk of dependence it should not be continued in general beyond six days.
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